ACST Stock – (NASDAQ: ACST) is actually providing an update on the use
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the usage of its “at-the market” equity offering plan.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. along with H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to implement a “at the market” equity offering program under which Acasti may well issue and market from time to time its common shares having an aggregate offering price of up to $75 million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions found on January 27, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares were offered at prevailing market costs averaging US$1.0747 a share. No securities had been sold throughout the facilities of the TSXV or perhaps, to the expertise of the Company, in Canada. The ATM Shares were offered pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was paid to the Agents in connection with the services of theirs. As a direct result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and great as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and often will provide the Company with additional flexibility in its ongoing review process to explore and evaluate strategic options.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically concentrated on the research, development and commercialization of prescription medications making use of OM3 fatty acids delivered both as free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical proof of efficacy and safety for lowering triglycerides in people with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements in this press release that aren’t statements of historical or current fact constitute “forward looking information” within the meaning of Canadian securities laws and “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking assertions involve known and unknown risks, uncertainties, along with other unknown variables that might result in the particular results of Acasti to be materially different from historical success and from any future results expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe these kinds of risks as well as uncertainties, people are urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other related expressions to be uncertain and forward-looking. People are actually cautioned not to place undue reliance on these forward looking statements, which speak only as of the date of this particular press release. Forward-looking claims in that press release include, but are not limited to, information or statements about Acasti’s strategy, future operations as well as the review of its of strategic options.
The forward looking assertions contained in this specific press release are expressly qualified in the entirety of theirs by this cautionary declaration, the “Special Note Regarding Forward Looking Statements” area in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor section of Acasti’s website at www.acastipharma.com. Many forward looking statements in that press release are made as of the date of this particular press release.
ACST Stock – Acasti doesn’t undertake to upgrade any such forward looking statements whether as a result of info which is new, future events or perhaps otherwise, except as needed by law. The forward looking assertions contained herein are also subject generally to risks and assumptions as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, including Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage